Cryptosporidium parvum oocysts (ABO809)

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

5 competitors in Cryptosporidiosis

#DrugCompanyPhaseTrials

1

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

32

EDI048

Novartis

Phase 2

13

Cryptosporidium parvum oocysts (ABO809)

Novartis

Phase 2

14

Diclazuril

Johnson & Johnson

Preclinical

25

Spiramycin

RRhone-Poulenc Rorer

Preclinical

16

Interleukin-12

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Study of Efficacy and Safety of ABO809 in Healthy Participants

Completed·Novartis·Phase 1·NCT05036668·30 enrolled

Cryptosporidiosis1 trial

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Assess the Efficacy and Safety and Tolerability of EDI048 in a Cryptosporidium Controlled Human Infection Model (CHIM) in Healthy Participants

Recruiting·Novartis·Phase 2·NCT07249463·80 enrolled

Details

Drug Info

Related News